Consensus EPS · Q1 2026
$2.21
Consensus revenue · Q1 2026
$95B
Analysts
16
Expected report
May 6, 2026
Analyst consensus (locked)
Analyst consensus
Based on estimates from 16 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $91B | $95B | $98.8B |
| EPS | $2.10 | $2.21 | $2.38 |
| EBITDA | $3.9B | $4B | $4.1B |
| EBIT | $2.7B | $2.8B | $2.9B |
| Net income | $2.6B | $2.8B | $3B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q4 2025 | $105.7B | $103.7B | +1.9% | $1.09 | $1.00 | +8.7% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for CVS Health (CVS) Q1 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 11 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $90.00 | $102.67 | $106.00 | $113.00 | $95.93 | +7.0% |
Upside calculated vs most recent trading price of $95.93.
Analyst ratings
Consensus: Buy — based on 41 analyst ratings.
12-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jun 1, 2026 | Truist Securities | maintain | Buy | Buy |
| May 26, 2026 | Barclays | maintain | Overweight | Overweight |
| May 20, 2026 | Mizuho | maintain | Outperform | Outperform |
| May 14, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| May 13, 2026 | Bernstein | maintain | Outperform | Outperform |
| May 12, 2026 | JP Morgan | maintain | Overweight | Overweight |
| May 11, 2026 | TD Cowen | maintain | Buy | Buy |
| May 8, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| May 7, 2026 | UBS | maintain | Buy | Buy |
CVS Health (CVS) Key Financials
Charts, filings, and peer comparison for every metric
Frequently asked questions
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation